

Algernon Pharmaceuticals Inc.

09:59 09 Nov 2020

Algernon to share interim data from Phase 2b/3 human study of Ifenprodil to treat COVID-19 in December

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) (FRA:AGW) said Monday that it plans to conduct an interim data review of its multinational Phase 2b/3 human trial of its lead drug NP-120 (Ifenprodil) as a potential treatment for coronavirus (COVID-19) sufferers.

In a statement, the Vancouver clinical-stage pharma company said it will look at the primary endpoint of the World Health Organization (WHO) ordinal score and also secondary endpoints, including the number of days that patients were in the intensive care unit and the hospital, as well as the number of days patients were on mechanical ventilation, and oxygen.

The data, from 75 patients on day 15 of the study, will be presented in a descriptive statistics format and Algernon is projecting the data readout will be in the first week of December 2020.

READ: Algernon enrolls 100 patients for its Phase 2b/3 human study of Ifenprodil to treat COVID-19

Algernon said it decided to conduct an enhanced interim data readout because of the surge in serious cases as a result of the second wave of the pandemic, the number of safety issues with vaccine and antibody trials, and the firm's belief that Ifenprodil has the potential to reduce the severity of a COVID-19 infection.

"With the quickly increasing global threat from COVID-19, we believe we have an obligation to find out now how our COVID-19 trial is trending," said Algernon Pharmaceuticals CEO Christopher J. Moreau.

"If Ifenprodil has been performing well in the study, this early look at the data may allow us to accelerate our COVID-19 program accordingly," he added.

Phase 2b/3 study protocol

The company's multinational Phase 2b/3 trial has begun as a Phase 2b study with 150 patients. With positive data, the clinical trial will move directly into a Phase 3 trial. The data from the Phase 2b study will determine the number of patients needed to reach statistical significance in the Phase 3 trial.


Patients are being randomized in a one-to-one manner and will either be treated using an existing standard of care, or standard of care plus Ifenprodil 60 mg (taken as one 20 mg tablet three-times daily) for one arm or standard of care plus Ifenprodil 120 mg (taken as two 20 mg tablets three-times daily) for two weeks.

The company noted that over the testing period, doctors will observe whether there is an improvement in a number of secondary endpoints, including "mortality, blood oxygen levels, time spent in intensive care and time to mechanical ventilation."

Price: 0.235

Market Cap: \$32.51 m

1 Year Share Price Graph



January 2020 July 2020 January 2021

Share Information

Code: AGN

Listing: CSE

52 week High Low
0.58 0.065

Sector: Pharma & Biotech

Website: algernonpharmaceuticals.com

Company Synopsis:

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on the areas of non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) and inflammatory bowel disease (IBD). Algernon's key compounds were identified using a drug repurposing strategy.

action@proactiveinvestors.com

Algernon believes that Ifenprodil could reduce the infiltration of neutrophils and T-cells into the lungs, where they can release glutamate and cytokines. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function, and ultimately death, in COVID-19 patients.

Algernon is also steadily advancing its lead drug NP-120 (Ifenprodil) as a possible treatment for idiopathic pulmonary fibrosis, acute lung injury, and chronic cough.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).